EssilorLuxottica S.A., FR0000121667

EssilorLuxottica stock: HSBC cuts rating, target to EUR 190

Published on 11/18/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
EssilorLuxottica stock faced a lower HSBC view on Tuesday. The group had reported stronger nine-month sales in October.

HSBC changes its stance

  • HSBC lowered its recommendation on EssilorLuxottica from Buy to Hold on November 17.
  • EssilorLuxottica reported nine-month sales growth of 6.8 percent in October, supported by direct-to-consumer activity.
EssilorLuxottica S.A., FR0000121667, Illustration mit AI erstellt.

HSBC lowered its recommendation on EssilorLuxottica from Buy to Hold on Tuesday, November 17, while cutting its price target from EUR 200 to EUR 190, according to Ideal Investisseur. The analyst action gives investors a more cautious near-term valuation reference after the shares' strong rebound from their October lows.

HSBC lowers rating and target

The report said HSBC had previously rated the shares Buy. Its revised Hold view was accompanied by a 5 percent reduction in the target price, according to the same report. The change came during a weaker session for French equities, with EssilorLuxottica among the larger decliners in the CAC 40.

Ideal Investisseur reported that the shares were down 3.09 percent at EUR 178.80 at the close on November 17. The article also said the stock remained 16.55 percent above its level one month earlier, highlighting the scale of the recovery that preceded the analyst change.

Sales momentum remains in focus

The analyst action follows EssilorLuxottica's third-quarter sales announcement on October 20. The company's investor relations page lists that release as the latest financial event and identifies the group as a global eyecare and eyewear company.

For the first nine months of 2026, revenue reached EUR 22.304 billion, up 6.8 percent, according to the report. Direct-to-consumer sales rose 10.6 percent in the third quarter, while like-for-like sales in that segment increased 6.8 percent. Myopia-management solutions grew 24 percent over the first nine months, and the traditional Eyecare and Medtech activities expanded by more than 6 percent in both the third quarter and the nine-month period.

Those operating figures provide the main counterweight to the more cautious valuation view. The company is delivering growth across core eyewear and newer health-related activities, while the analyst revision places greater emphasis on the amount of near-term upside available to shareholders.

What investors watch next

EssilorLuxottica stock traded at 180.28 euros on Lang & Schwarz at 10:12 CET on Wednesday, November 18. The quoted level was above the previous Lang & Schwarz close of 178.30 euros, but that comparison is not an Xetra closing-price measure.

EssilorLuxottica stock at a glance

  • Company: EssilorLuxottica
  • ISIN: FR0000121667
  • Lang & Schwarz quote: 180.28 euros at 10:12 CET on November 18, 2026
  • Prior Lang & Schwarz close: 178.30 euros
  • Analyst action: HSBC moved the rating from Buy to Hold on November 17, 2026

The wider French equity market was weaker in the same session, with the CAC 40 declining 1.62 percent at the close, according to the market report. Investors will weigh the slower valuation signal from HSBC against EssilorLuxottica's continued sales growth and its exposure to myopia management, direct-to-consumer retail and smart eyewear.

More news and analyses on EssilorLuxottica stock

Disclaimer...
en | FR0000121667 | ESSILORLUXOTTICA S.A. | boerse | 70530344 | bgmi